AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Core EPS: $2.63 in Q2 2026, up 21.2% from a year earlier. That is the highest of the 23 quarters on record here.
Latest, Q2 2026
2.63
Period ended Jun 30, 2026
Change on a year earlier
+21.2%
2.17 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below
Where the Q2 2026 figure comes from
“|| EPS | | $ | 1.61 | | $ | 0.05 | | $ | 0.79 | | $ | 0.18 | | $ | 2.63 | 21 | 18”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Core Financial Measures.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up core EPS
Cite this data
StockData. (2026). AstraZeneca Core EPS ($), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core-eps
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.